Immunovaccine, Inc. (OTC: IMMVF) develops cancer immunotherapies and infectious disease vaccines based on the company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through phase 1 human clinical trials and is currently conducting a phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer). Immunovaccine is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax. For more information, visit the company’s website at www.imvaccine.com